The free fatty acid receptor 1 (FFA1/GPR40) is a potential target for treatment of type 2 diabetes. Although several potent agonists have been described, there remains a strong need for suitable tracers to interrogate ligand binding to this receptor. We address this by exploring fluorophore-tethering to known potent FFA1 agonists. This led to the development of 4, a high affinity FFA1 tracer with favorable and polarity-dependent fluorescent properties. A close to ideal overlap between the emission spectrum of the NanoLuciferase receptor tag and the excitation spectrum of 4 enabled the establishment of a homogenous BRET-based binding assay suitable for both detailed kinetic studies and high throughput competition binding studies. Using 4 as a tracer demonstrated that the compound acts fully competitively with selected synthetic agonists but not with lauric acid and allowed for the characterization of binding affinities of a diverse selection of known FFA1 agonists, indicating that 4 will be a valuable tool for future studies at FFA1.
INTRODUCTION
Free fatty acid receptor 1 (FFA1, also known as GPR40) is a 7TM receptor activated by medium-and long-chain free fatty acids that in recent years has attracted much attention as a potential target for the treatment of type 2 diabetes. FFA1 is highly expressed in pancreatic ² -cells where it enhances insulin secretion in a glucose concentration-dependent manner. It may therefore represent a target for safe new insulin secretagogues devoid of the risk of hypoglycemia associated with the currently used sulfonamides.
1 FFA1 is also highly expressed in enteroendocrine cells and regulates incretin hormone secretion, driving further interest in this receptor as a target for type 2 diabetes. 2 Proof of this concept was recently provided from clinical trials with 1 (TAK-875/fasiglifam), a selective FFA1 agonist that showed glucose lowering activity similar to the sulfonylurea glimepiride without the increased hypoglycemic events observed with glimepiride. 3 Originally derived from the structure of docosahexaenoic acid (DHA), 4 the pharmacology of 1 has turned out to be more complex than previously presumed.
Rather than binding to the orthosteric free fatty acid binding site on FFA1, 1 was recently shown to be an allosteric agonist with the ability to positively modulate fatty acid actions at FFA1. 5 In fact, studies using radiolabeled ligands have indicated that FFA1 possesses at least three distinct binding sites that recognize structurally closely related ligands and that each site is able to allosterically modulate ligand function at the others. 6 The recently published crystal structure of FFA1 in complex with 1 lent further support to the concept of multiple FFA1 binding sites, revealing several potential binding sites in addition to the site of 1. 7 Most importantly from a drug development standpoint, the specific binding site an FFA1 agonist interacts with may influence the ligand's downstream signaling outcomes, 2c and thus may have clear implications for the ultimate therapeutic efficacy of any developed FFA1 agonists. How these structurally similar ligands interact with their distinct binding sites on FFA1 remains poorly understood and, therefore, there is a clear need to develop novel tools to assess ligand binding to this receptor.
Ligands incorporating fluorescent probes have become common tools to assess ligand binding to GPCRs and offer a number of advantages over classic radiolabeled ligands. 8 In addition to practical considerations of convenience, safety and cost, by utilizing solvatochromic fluorophores or combining with a resonance energy transfer assay format, fluorescent ligands provide the significant advantage of real-time detection of their binding. This allows for homogenous assay formats, improved measurements of ligand binding kinetics, and
visualizations of receptor-ligand complexes within a living cell. [8] [9] Fluorescently-tagged FFA1
ligands are, therefore, expected to be valuable tools for elucidation of the pharmacology of this very interesting antidiabetic target.
Choice of fluorophore
Commonly used fluorophores include relatively large structures such as fluorescein derivatives and especially BODIPY (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) due to its several favorable properties. 10 The smaller benzofurazan core structure is also well-known in fluorogenic and fluorescent reagents and represents a class of compounds that results in derivatives with good quantum yields and with excitation and emission wavelengths long enough to avoid interference from biological autofluorescence. 11 Variation of substituents in the 4-and 7-position influences the electronic effects on the system and thereby the fluorescent properties. 12 In this way the excitation and emission maxima as well as fluorescent intensity can be modified. The 4-nitro-7-aminobenzofurazan (NBD) fluorophore is a relatively small fluorescent probe with excitation maximum around 470 nm and emission maximum around 530 nm when substituted with an amine in the 7-position, 13 wavelengths well suited to in vitro biological systems. Furthermore, NBD is solvatochromic, exhibiting very low fluorescent activity in polar and protic environments, but much increased fluorescence in hydrophobic environments such as protein binding pockets or the plasma membrane. 14 These properties suggest an NBD fluorescent tracer may possess reduced background fluorescence from non-bound fluorescent tracer allowing for both homogenous detection and use in imaging applications. NBD has been used previously for labeling small amine containing molecules and proteins used in binding assays as well as for visualization in living cells.
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Design of fluorescent FFA1-tracers
We have previously reported on two series of agonists for FFA1 based on an alkyne scaffold and a benzyloxy/benzylamine scaffold, respectively, and we aimed at exploring both series in efforts to develop a potent fluorescent tool compound for FFA1 (Figure 1 ). The first fluorescent tracer 2 is based on the alkyne series that includes 3 (TUG-770), a
compound showing good potency and lower lipophilicity than most other FFA1 agonists. 16 This is important because incorporation of a fluorophore generally erodes potency and, for uncharged fluorophores, increases lipophilicity of the compounds thereby reducing their usefulness for in vitro pharmacology studies. Structure-activity relationship (SAR) investigations have shown that larger substituents at the alkyne scaffold are best tolerated in the meta-position of the terminal phenyl ring, but these lead to a loss in potency, which to some extent can be regained by introduction of a 2-fluoro substituent on the central phenyl ring. [16] [17] Thus, the 2-fluoro substituent was incorporated in the target structure and the spacer-extended fluorophore was attached to the meta-position of the terminal phenyl ring. A shorter 2-aminoethoxy and a longer 2-(2-aminoethoxy)ethoxy tether were considered, however, the NBD-tethered compounds with the shorter 2-aminoethoxy spacer turned out to be unstable and decomposed before or during purification. Focus was therefore directed towards the longer linker.
The second fluorescent tracer 4 was designed based on the benzylamine agonist 5 (TUG-905), a potent and selective agonist on both the human and rodent FFA1 receptors. 18 The 2-fluoro substituent, shown to significantly enhance potency in the alkyne series, 16 also in some cases enhances potency in the benzylamine and benzyloxy series and was incorporated in the target structure. The amine-linker was exchanged for the corresponding oxy-linker since this facilitates preparation and the modification has been shown to have only modest effect on ligand potency. 19 The mesylpropoxy appendage also present in the structurally related agonist 1, has been found to reduce lipophilicity of the compounds with little or no effect on potency. 4b, 18 The crystal structure of FFA1 in complex with 1 provided an explanation for this in showing the mesylpropoxy appendage to be protruding from the ligand binding pocket towards the lipid bilayer. 7 Thus, this seems to be an optimal linkage point for attachment of a spacer-extended fluorophore. In order to gain optimal fluorescent properties of the NBD fluorophore the compound should be attached to a primary aliphatic amine. 12 Thus, we decided to explore 2-(2-aminoethoxy)ethanol, which is slightly longer than the mesylpropoxy substituent but less lipophilic than an all carbon linker.
RESULTS AND DISCUSSION
Synthesis of tracer ligands
The fluorescent tracer molecules 2 and 4 were synthesized by similar strategies. and further by a two-step one-pot borylation Suzuki cross-coupling using tetrahydroxydiboron as borylation agent and the second generation XPhos precatalyst to give 10 (Scheme 2). 21 The fluorophore was installed by alkylation of the phenol of 10, deprotection of 11 and reaction with NBD chloride, as described for 2, to provide 4 in 8% overall yield from 8. 
Characterization of fluorescent properties
The fluorescent properties of the ligands were examined in Hanks' balanced salt solution (HBSS) supplemented with calcium and magnesium, a standard aqueous buffer used for our in vitro pharmacological assays, and n-octanol mimicking a lipophilic environment to examine the solvatochromic effect of NBD.
The excitation and emission maxima of 2 in n-octanol were within the desired range giving an acceptable Stokes shift (SS) of 64 nm (Table 1) . As expected, the excitation and emission maxima were somewhat red-shifted in the aqueous medium (» ex = 483 nm & » em = 546 nm, Table 1 and Figure S1 ). Compound 4 showed excitation and emission maxima similar to 2 in both n-octanol and HBSS (SS = 65 nm, Figure 2A) , however, the extinction coefficient was 2.7-fold higher for 4. To investigate the influence of the solvatochromic effect of NBD, emission spectra of 4 were recorded in both n-octanol and HBSS using identical instrument settings. This showed, as expected, almost no fluorescent activity in the aqueous environment ( Figure 2B) 
Functional characterization of 2 and 4
Initial functional characterization of 2 established that although the fluorophore remained an FFA1 agonist, it had substantially reduced potency compared to the parent compound 3. Indeed, its potency was too low to establish an accurate EC 50 value (Table 1, Figure 3A ). In contrast, while 4 also behaved as an agonist, this compound retained high potency, displaying only a small reduction compared to its parent 5 (Table 1, Figure 3B ). This suggests the position of the linker and the NBD fluorophore in 4 has minimal impact on its interaction with FFA1, and that the molecule is likely to be a useful FFA1 tracer. 
Characterization of 4 as an FFA1 tracer
Based on its high potency in the Ca 2+ assay we developed an FFA1 binding assay utilizing this ligand as a tracer employing a bioluminescence resonance energy transfer (BRET)-based approach. 22 This allows for a truly homogeneous 'mix and measure' assay, well suited for both detailed kinetic as well as high throughput equilibrium binding experiments. For this, FFA1 was tagged at its N-terminus with the small, bright NanoLuciferase (NLUC), a bioluminescent enzyme with an emission spectrum that has excellent overlap with the NBD excitation spectrum ( Figure 5A ). Thus, when 4 binds to NLUC-FFA1, energy transfer at 460 nm can occur between the NLUC and NBD moiety, resulting in NBD emission at 545 nm. As BRET is strictly dependent on the distance between the bioluminescent and fluorescent partners, this approach eliminates the need to remove 4 from the assay medium and limits any signal obtained from the non-specific binding of 4 to the membrane ( Figure 5B ). finding is consistent with previous reports that the fatty acids bind to a different site than many synthetic FFA1 agonists. [5] [6] Global curve fitting to an allosteric ternary complex model of the lauric acid data allowed for an estimation of its pK B (4.46 ± 0.15) and allosteric cooperativity factor (logα = -0.29 ± 0.09) values.
Given that we observed all synthetic agonist classes to be competitive with 4, we next aimed to use this compound to assess the affinity of a range of previously reported FFA1 agonists. For these studies, in addition to parent compounds and analogues of 2 and 4, the first high-potency FFA1 agonist 12, the previous clinical candidates 13 (AMG-837) 24 and 1, and Merck's potent thiazolidinedione agonist 14 (Cmp B) 25 were selected. [23] [24] [25] [26] Each of the selected molecules exhibited competitive binding with 4 that allowed estimation of K i binding affinity constants (Table 2) . β-arrestin pEC 50 determined using BRET-β-arrestin recruitment assay. E max expressed as % of 3, n = 3. c Ca 2+ pEC 50 were determined using FFA1-expressing 132N1 cells. E max is expressed as % of 3. n = 3.
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Partial competition that fitted to an allosteric ternary complex model gave pK B = 4.46 and logα = -0.29 (see Figure S2 ).
Overall, good correlation between agonist potency and binding K i -values was observed, with 5 being both the most potent agonist in the functional assays and the ligand with the highest affinity (Table 2) . Likewise, 1 and 13 showed K i -values that were similar to their functional potency, and also similar to K i -values previously established through a radiotracer competition binding assay. 2c 14, which with a different core structure and a thiazolidinedione head group is the most structurally distinct from 4, also exhibited potency in the functional assays that corresponded well to its binding affinity. In contrast, 3, a highly potent agonist in both Ca 2+ and β-arrestin-2 interaction-based functional assays, showed a 15-and 3-fold lower potency, respectively, in the binding assay. A similar observation was made with 12, also showing a much lower affinity for FFA1 than would be expected based on the functional data.
To examine the discrepancy between potency and affinity of 3 more closely, derivatives of 3 and 5 with varying functional potency were tested in competition binding assays. These studies The discrepancy between affinity and potency across chemical series may be explained by differences in the intrinsic efficacy of these series to activate FFA1. Although all agonists tested appeared to be equal and full agonists in the Ca 2+ assay, it is well established that in Ca 2+ assays, which have a high level of signal amplification, differences in intrinsic efficacy of a ligand will often manifest as increased potency, due to the presence of a receptor reserve. 28 It could also be related to kinetic properties where slow and fast ligands may have distinct functional activities but will appear to have the same affinity as long as the ratios between their on-and off-rates are the same. It is therefore possible that at least some aspects of the discrepancy between potency and affinity observed for certain chemical series of FFA1 agonists could be related to binding kinetics. A third factor that may contribute to the discrepancy is the apparent presence of the multiple binding sites in FFA1, [5] [6] implying the possibility of partial or lack of overlap with 4. In line with these observations, lauric acid was found to behave as an allosteric compound incompetent to fully displace 4, in contrast to the synthetic agonists that all behaved as fully competitive with 4, indicating at least partially overlapping binding sites. Taken together, these findings demonstrate that a full characterization of both binding affinity and functional potency will be critical to understanding the pharmacology of novel FFA1 compounds. This establishes 4 as a valuable tool in future drug discovery efforts targeting FFA1.
EXPERIMENTAL SECTION Synthesis
Commercial starting materials and solvents were used without further purification, unless otherwise stated. THF was freshly distilled from sodium/benzophenone. 
3-(2-Fluoro-4-((3-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)ethoxy)-phenyl)ethynyl)phenyl)propanoic acid (2).
Step 1: 7 (176 mg, 0.36 mmol) was dissolved in THF (4 mL). 4M HCl (aq) (2 mL) was added and the reaction was heated to reflux for 2½ h. After complete hydrolysis the reaction was cooled to room temperature and 2M NaOH (aq) (4 mL) was added. The mixture was extracted with EtOAc (x3). Additional 2M NaOH (aq) (2 mL) was added to the water phase and this was extracted once more with EtOAc (x3 Step 2: A dry microwave vial under argon atmosphere was charged with the deprotected crude 
3-(2-Fluoro-4-((2'-methyl-4'-(2-(2-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)ethoxy)ethoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)propanoic acid. (4)
Step 1:
Boc-protected amine 11 (83 mg, 0.14 mmol) was dissolved in THF (1.7 mL) and 4M HCl aq (0.8 mL) was added. The reaction was refluxed for 7 hours and after completion cooled to room temperature. 2M NaOH aq (3 mL) was added and the mixture was extracted with EtOAc/MeOH (9:1, x3). The organic phases were collected, dried over Na 2 SO 4 and concentrated in vacuo giving the zwitterion as a beige solid that was used directly in the next step.
Step 2: A dry flask under argon with magnetic stirring bar was charged with the crude material from
Step 1 (0.14 mmol), MeOH (3.7 mL), NaHCO 3 (37 mg, 0.45 mmol) and 4-chloro-7- 
Characterization of excitation and emission properties of fluorescent ligands for FFA1
Absorbance curves and extinction coefficients for fluorescent ligands dissolved in either noctanol or HBSS (with Ca 2+ and Mg 2+ ) were measured in triplicate using a FLUOstar Omega
Microplate Reader (BMG LAB-TECH).
Emission curves for fluorescent ligands were measured in duplicate using a ChronosFD timeresolved spectrofluorometer coupled to PMT detectors. All compounds were excited at a fixed excitation wavelength of 402 nm, and courmarin 153 (C-153) in EtOH was used as an internal standard for determination of quantum yield (¦ C-153 = 0.546, » ex = 402 nm) 29 . All experiments were performed at 25°C. 
Development of NLUC-FFA1 construct and cell line
In order to develop a BRET binding assay a DNA construct was first generated using a 
Equilibrium BRET binding assay
NLUC-FFA1 Flp-In T-REx 293 cells were induced to express the receptor construct by treatment for 24 h with 100 ng/ml doxycycline. Cells were then harvested and used to make total cell membrane preparations according to a previously described protocol. 30 Membranes were then resuspended in assay buffer (50 mM HEPES, 100 mM NaCl, 10 mM CaCl 2 , 10 mM MgCl 2 ) and distributed into the wells of a white 96 well plate (5µg membrane protein/well). Membranes were then co-incubated with the indicated concentration of 4 (and 5 for non-specific binding measurements; or competing ligand for competition experiments) for 1 h at 25 °C. Following incubation, the NLUC substrate, Nano-Glo (Promega) was added to a final 1:800 dilution.
Membranes were incubated a further 5 minutes before the bioluminescent emission at 460nm
and 545 nm was measured using a Clariostar plate reader (BMG labtech). The ratio of 545/460
was then background subtracted and multiplied by 1000 to yield 'Net mBRET' units. Total and non-specific saturation binding data were then globally fit to a one-site binding model using 
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Absorption & emission spectra of 2 Figure S1 . Normalized absorption and emission spectra of 2. n-octanol, Hank's buffer, solid line ~ excitation, dotted line ~ emission.
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Competition binding curves for synthetic agonists and lauric acid Figure S2 . The synthetic agonists 1 (TAK-875), 3 (TUG-770), 5 (TUG-905) and 12 (GW9508), but not the saturated fatty acid, lauric acid, bind competitively to FFA1 with 4. Competition BRET binding curves were generated using 5, 30 and 100 nM concentrations of 4 against 1 (A), 3 (B), 5 (C), 12 (D), and lauric acid (E). Each of the synthetic ligands in A-D fully displaced 4 at all three concentrations, and therefore data were fit to determine pK i . Lauric acid did not fully compete with 4, and therefore was fit to an allosteric ternary complex model to determine pK B and logα. Data shown are representative of triplicate experiments. 
